Ipatasertib dihydrochloride is primarily used in the field of oncology, specifically for the treatment of various types of cancer. It functions as an AKT inhibitor, targeting the AKT pathway which is often dysregulated in cancer cells, leading to uncontrolled cell growth and survival. This compound is particularly investigated in clinical trials for its efficacy in treating breast cancer, prostate cancer, and other solid tumors. By inhibiting the AKT pathway, it helps to induce apoptosis in cancer cells and can enhance the effectiveness of other cancer therapies, such as chemotherapy and radiation. Its application is crucial in developing targeted therapies that aim to improve patient outcomes with fewer side effects compared to traditional treatments.